Radiopharm Theranostics RAD 101 hits primary endpoint in 90% of brain metastasis patients at second Phase 2b interim analysis

Radiopharm Theranostics Limited (ASX: RAD, NASDAQ: RADX), a clinical-stage radiopharmaceutical company developing oncology imaging and therapeutic agents, on 24 March 2026 announced second interim data from its U.S. Phase 2b clinical imaging trial of RAD 101 in brain metastases, with 18 of 20 evaluable patients achieving concordance between RAD 101 PET imaging and contrast-enhanced MRI, the study’s primary endpoint. The 90% concordance rate represents a strong signal that RAD 101, a Fluorine-18-labelled small molecule targeting fatty acid synthase, may provide meaningful diagnostic value in a disease setting where standard MRI often produces equivocal results. Radiopharm Theranostics shares on NASDAQ surged more than 160% to approximately USD 11.19 intraday on the announcement, from a prior close of USD 4.28, reflecting the market’s sharp reassessment of clinical risk ahead of the full 30-patient data readout expected by June 2026. The result positions Radiopharm Theranostics as one of a small number of clinical-stage companies pursuing purpose-built PET tracers for brain metastasis diagnosis, a gap that existing FDG-based imaging has long struggled to fill adequately.

Why does 90% PET-MRI concordance in brain metastases matter for oncology diagnostic standards and treatment planning?

The diagnostic problem RAD 101 is designed to solve is not obscure. In the United States alone, more than 300,000 patients receive a diagnosis of cerebral metastases annually, and the incidence of intracranial metastatic disease continues to rise, partly because improved systemic therapies are enabling patients with primary solid tumours to live longer. Contrast-enhanced MRI is the standard imaging method for monitoring brain metastases, but it has a recognised limitation: distinguishing between true tumour recurrence and radiation necrosis, a tissue injury caused by stereotactic radiosurgery, is notoriously difficult on MRI alone. Equivocal findings force clinicians into a diagnostic bind between watchful waiting, repeat imaging, and biopsy, each carrying its own burden for patients who are already managing advanced cancer.

RAD 101 approaches this problem through fatty acid synthase, an enzyme that is overexpressed in many solid tumour types including brain metastases. By radiolabelling a small molecule targeting fatty acid synthase with Fluorine-18 and using PET imaging, Radiopharm Theranostics is attempting to make metabolically active tumour tissue visible in a way that anatomical MRI cannot reliably achieve. The second interim analysis showed significant and selective tumour uptake in PET images, with the Company noting that RAD 101 confirmed metabolic activity in lesions that appeared equivocal on MRI. For oncologists managing patients post-stereotactic radiosurgery, that differentiation is clinically material, as the treatment decision for recurrence versus radiation necrosis differs substantially.

How does the RAD 101 Phase 2b interim analysis compare with earlier Imperial College London data and what do sensitivity and specificity signals indicate?

The current U.S. Phase 2b trial, a multicenter, open-label, single-arm study enrolling 30 patients with confirmed recurrent brain metastases from solid tumours of different origins, builds on earlier Phase 2a work conducted at Imperial College London. That prior study demonstrated significant tumour uptake of 18F-RAD101 independent of the tumour’s primary origin, a property that matters because brain metastases arise from multiple cancer types including lung, breast, and renal cell carcinoma. Radiopharm Theranostics has previously indicated the Imperial College data also suggested that PET-MRI fusion could potentially serve as a non-invasive predictor of overall survival, a claim that would require considerably larger study populations to validate but which frames the longer-term ambition for the asset.

The current second interim analysis covers 20 patients, with 18 achieving the primary endpoint. Beyond concordance, the secondary endpoints of sensitivity and specificity are being evaluated in the subset of patients who have reached six months of follow-up or have available biopsy data. With five such patients evaluable at this interim cut, Radiopharm Theranostics described a positive trend for both measures without disclosing specific rates. Sensitivity measures a test’s ability to correctly identify patients with tumour recurrence (true positive rate), while specificity captures accurate identification of patients without recurrence (true negative rate). Both are prerequisites for regulatory credibility, and the early directional signal matters because a diagnostic agent with strong concordance but poor sensitivity or specificity would have limited clinical utility and would face a significantly harder path through FDA review.

What does FDA Fast Track Designation mean for RAD 101’s regulatory path and how does it affect Radiopharm Theranostics’ timeline to commercialisation?

RAD 101 holds FDA Fast Track Designation, awarded specifically to distinguish between recurrent disease and treatment effect in brain metastases originating from solid tumours of different origins, including leptomeningeal disease. Fast Track status is a process designation, not an approval, but it provides meaningful procedural advantages: more frequent interactions with FDA reviewers, eligibility for rolling review of marketing applications, and, if criteria are met, possible eligibility for Accelerated Approval or Priority Review. For a small clinical-stage company with a narrow cash runway, the reduction in review cycle time and improved visibility into regulatory expectations can materially alter the risk-adjusted commercial timeline.

The Company has indicated the final data readout from the full 30-patient study is expected by June 2026, with that data set to inform decisions on whether and how to proceed to a pivotal trial. A pivotal trial would be the prerequisite step for a New Drug Application submission, and the design of that trial, particularly its size, endpoints, and comparator arms, will be a significant determinant of capital requirements and partner interest. For Radiopharm Theranostics, the June readout therefore carries dual weight: clinical validation and fundraising catalyst, in a sector where investor appetite for radiopharmaceutical diagnostics has been rising but where clinical-stage biotech funding remains highly sensitive to data quality and statistical rigour.

How does Radiopharm Theranostics’ RAD 101 strategy fit within the broader radiopharmaceutical sector and what competitive threats does the company face?

The global radiopharmaceuticals market was valued at approximately USD 7.6 billion in 2024 and is projected to expand at a compound annual growth rate of roughly 10% through 2033, driven by oncology applications, aging populations, and the commercial success of approved radioligand therapies such as Novartis’s lutetium-177 PSMA therapy for prostate cancer. Within diagnostics specifically, the PET radiopharmaceutical segment is forecast to approach USD 3 billion by 2034. The sector has attracted capital at scale, with Novartis, Bayer, Lantheus Holdings, and Eli Lilly all building or acquiring significant radiopharmaceutical positions. The radiopharmaceutical landscape for brain metastases diagnosis, however, is considerably less crowded.

Standard FDG-PET, the dominant PET tracer globally, is poorly suited to brain imaging because the brain’s baseline glucose metabolism is high, reducing contrast between tumour and normal tissue. This creates a genuine unmet need that RAD 101’s FASN-targeting mechanism is designed to address. No major approved PET tracer is specifically indicated for differentiating recurrent brain metastases from radiation necrosis in the way Radiopharm Theranostics is pursuing. Telix Pharmaceuticals, Clarity Pharmaceuticals, and Blue Earth Diagnostics are active in adjacent PET diagnostic spaces, primarily prostate cancer and neuroendocrine tumours, but none has an equivalent programme in this specific brain metastasis indication. For Radiopharm Theranostics, that absence of direct competition is both an opportunity and a validation challenge: the regulatory and clinical pathway must be built largely from first principles.

What does the RADX stock surge on March 24 reveal about market pricing of clinical risk and what execution risks remain before a pivotal trial?

RADX on NASDAQ entered the trading session on 24 March 2026 at a prior close of approximately USD 4.28, with the stock having ranged between USD 3.50 and USD 11.00 over the preceding 52 weeks. By midday, RADX had surged to approximately USD 11.19, a move of more than 161%, on extraordinarily elevated volume of over 30 million shares against an average daily volume of well under one million. The stock’s intraday high reached USD 16.24. On the ASX, where Radiopharm Theranostics trades as RAD, the stock had been hovering around A$0.03, reflecting the thin liquidity and fractional price that characterises many Australian-listed preclinical and clinical-stage biotechs.

The magnitude of the price move reflects two things simultaneously. First, the market had been pricing in material probability of failure or delay, given that RADX was trading near its 52-week low of USD 3.50 in recent months. Second, a positive interim result from a 20-patient cohort, while encouraging, is not equivalent to a completed pivotal trial, and the stock’s repricing is partly speculative positioning ahead of the June final readout. Analysts covering RADX, of whom three carry a consensus Strong Buy rating, had maintained an average 12-month price target of USD 14.33 prior to today’s announcement, suggesting the pre-announcement price reflected a significant discount to assessed fair value. Whether today’s price appreciation is sustained will depend on whether the June 30-patient final data maintains the 90% concordance rate and delivers more robust sensitivity and specificity numbers.

The material execution risks ahead are not trivial for a company of this size. Radiopharm Theranostics reported cash of USD 34.52 million as at 31 December 2025, a balance that provides a limited operational runway before additional capital is required. Designing and funding a pivotal trial for a novel PET diagnostic agent is capital-intensive. The Company will need either a substantial partnership, a licensing arrangement with a larger radiopharmaceutical platform player, or an equity raise, each of which introduces its own conditionality and dilution risk. Additionally, while FDA Fast Track Designation streamlines the review process, it does not guarantee approval, and the agency’s standards for diagnostic imaging agents include real-world clinical utility, reimbursement viability, and manufacturing scalability as considerations that sit beyond the clinical trial itself.

What is Radiopharm Theranostics’ broader pipeline and does RAD 101’s progress strengthen or narrow the company’s risk profile?

Radiopharm Theranostics operates a pipeline spanning four licensed platform technologies, with diagnostic-therapeutic pairing as the underlying architecture. The programme includes RAD 102, the therapeutic counterpart to RAD 101 using the same fatty acid synthase target, as well as candidates in breast cancer (HER-2 targeted), non-small cell lung cancer (PDL1 targeted), pancreatic cancer (Avss6-Integrin targeted), prostate cancer (PSA-mAb targeted), and glioblastoma (PTPmu targeted). The company has one Phase 2 trial and four Phase 1 trials active across solid tumour cancers including lung, breast, and brain metastases. The joint venture with MD Anderson Cancer Center, Radiopharm Ventures, is advancing a B7H3-targeting antibody radioconjugate programme with FDA IND clearance obtained for the lead candidate.

RAD 101’s interim success narrows the company’s near-term risk profile insofar as it validates the FASN-targeting mechanism in a clinically meaningful setting, which has indirect read-through to RAD 102’s therapeutic potential. However, a company running multiple early-stage programmes with a cash balance of approximately USD 34.5 million faces the classic capital allocation tension of a clinical-stage biotech: advance the most de-risked programme toward regulatory approval as quickly as possible, or maintain pipeline breadth to preserve optionality and partnering attractiveness. The June 2026 readout will be a pivotal decision point not only for RAD 101’s regulatory path but for how Radiopharm Theranostics prioritises capital and management bandwidth across its broader portfolio.

Key takeaways: What Radiopharm Theranostics’ RAD 101 interim data means for investors, neuro-oncology, and the radiopharmaceutical diagnostics sector

• RAD 101 achieved 90% PET-MRI concordance in 18 of 20 evaluable patients at the second interim analysis, representing a consistent and clinically meaningful result for a diagnostic agent targeting brain metastases.
• The primary endpoint result advances RAD 101 toward a full 30-patient readout expected by June 2026, which will determine whether the Company proceeds to a pivotal trial and, subsequently, an NDA submission.
• FDA Fast Track Designation reduces review timeline risk and signals regulatory alignment on the unmet medical need, but it is a procedural advantage, not an approval guarantee.
• Early sensitivity and specificity trends from five biopsy and follow-up patients are described as positive, a directional signal that matters for long-term clinical utility but remains preliminary at this sample size.
• RADX surged more than 161% to approximately USD 11.19 on 24 March 2026, from a prior close of USD 4.28, with the stock previously trading near its 52-week low, reflecting a sharp repricing of clinical risk.
• The brain metastasis PET diagnostic space has no directly competing approved product, as standard FDG-PET is poorly suited to brain imaging. RAD 101’s FASN-targeting mechanism addresses a genuine diagnostic gap.
• Global radiopharmaceuticals market is projected to grow from approximately USD 7.6 billion in 2024 to USD 16.9 billion by 2033, with diagnostics expected to hold the largest segment share, positioning a successful RAD 101 launch in a structurally growing market.
• Radiopharm Theranostics reported a cash balance of approximately USD 34.5 million at end of 2025, creating capital runway pressure as pivotal trial design and funding become the next critical milestone.
• The diagnostic-therapeutic pairing architecture means RAD 101 data has pipeline read-through implications for RAD 102, the FASN-targeting therapeutic candidate, potentially improving the company’s partnering position with larger radiopharmaceutical platform players.
• With three analyst recommendations at Strong Buy and a consensus 12-month price target of USD 14.33 prior to today’s announcement, the pre-announcement stock was pricing in significant discount to assessed fair value that today’s interim data has partially corrected.